ES2269711T3 - Inactivacion de genes de la via mep. - Google Patents

Inactivacion de genes de la via mep. Download PDF

Info

Publication number
ES2269711T3
ES2269711T3 ES02737952T ES02737952T ES2269711T3 ES 2269711 T3 ES2269711 T3 ES 2269711T3 ES 02737952 T ES02737952 T ES 02737952T ES 02737952 T ES02737952 T ES 02737952T ES 2269711 T3 ES2269711 T3 ES 2269711T3
Authority
ES
Spain
Prior art keywords
cells
lytb
mep
mep pathway
delta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02737952T
Other languages
English (en)
Spanish (es)
Inventor
Hassan Jomaa
Matthias Eberl
Boran Altincicek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioagency AG
Original Assignee
Bioagency AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2269711(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioagency AG filed Critical Bioagency AG
Application granted granted Critical
Publication of ES2269711T3 publication Critical patent/ES2269711T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES02737952T 2001-04-23 2002-04-13 Inactivacion de genes de la via mep. Expired - Lifetime ES2269711T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119905 2001-04-23
DE10119905A DE10119905A1 (de) 2001-04-23 2001-04-23 Inaktivierung von Genen des MEP-Wegs

Publications (1)

Publication Number Publication Date
ES2269711T3 true ES2269711T3 (es) 2007-04-01

Family

ID=7682435

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02737952T Expired - Lifetime ES2269711T3 (es) 2001-04-23 2002-04-13 Inactivacion de genes de la via mep.

Country Status (9)

Country Link
US (2) US7875279B2 (de)
EP (1) EP1381686B1 (de)
JP (1) JP4526763B2 (de)
AT (1) ATE334209T1 (de)
AU (1) AU2002312816A1 (de)
CA (1) CA2444955A1 (de)
DE (2) DE10119905A1 (de)
ES (1) ES2269711T3 (de)
WO (1) WO2002095011A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1408984E (pt) 2001-07-20 2008-12-26 Bioagency Ag Compostos organofosforosos para activar células t gama/delta
WO2009131730A2 (en) * 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
WO2011044505A2 (en) 2009-10-08 2011-04-14 Board Of Trustees Of The University Of Illinois Enzyme inhibiting compounds and methods
KR20200095534A (ko) 2017-12-07 2020-08-10 지머젠 인코포레이티드 발효에 의한 (6e)-8-히드록시제라니올의 제조를 위해 조작된 생합성 경로
WO2019126778A1 (en) 2017-12-21 2019-06-27 Zymergen Inc. Nepetalactol oxidoreductases, nepetalactol synthases, and microbes capable of producing nepetalactone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736981A1 (en) * 1998-04-14 1999-10-21 Kyowa Hakko Bio Co., Ltd. Process for producing isoprenoid compounds by microorganisms
EP1078045A1 (de) * 1998-05-13 2001-02-28 University Of Maryland College Park Methoden zur modifikation der herstellung von isopenyl-pyrophosphat, dimethylallyl-pyrophosphat und/oder isoprenoide
TR200103326T2 (tr) * 1999-05-21 2002-04-22 Jomaa Pharmaka Gmbh İsoprenoidin konsantrasyonunu değiştirmek için deoksi-D-ksiluloz fosfat biyosentetik yoluna ait genlerin kullanımı

Also Published As

Publication number Publication date
JP4526763B2 (ja) 2010-08-18
EP1381686A2 (de) 2004-01-21
AU2002312816A1 (en) 2002-12-03
US7875279B2 (en) 2011-01-25
CA2444955A1 (en) 2002-11-28
WO2002095011A2 (de) 2002-11-28
US20110129883A1 (en) 2011-06-02
EP1381686B1 (de) 2006-07-26
JP2004531264A (ja) 2004-10-14
US20080206267A1 (en) 2008-08-28
DE10119905A1 (de) 2002-10-24
WO2002095011A3 (de) 2003-11-20
DE50207641D1 (de) 2006-09-07
ATE334209T1 (de) 2006-08-15

Similar Documents

Publication Publication Date Title
ES2989085T3 (es) Composiciones para modular la actividad de citoquinas gamma-c
ES2393610T3 (es) Cepa de protozoo de la especie Leishmania infantum de virulencia atenuada y su utilización
ES3034676T3 (en) Inhibitors of arg1 and/or arg2
Black et al. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.
ES2834556T3 (es) Lípidos y formulaciones de nanopartículas lipídicas novedosos para la entrega de ácidos nucleicos
CN103641892B (zh) 用于治疗组织炎症和癌变的鸟苷酸环化酶受体激动剂
ES2402878T3 (es) Aislamiento de moduladores biológicos a partir de colecciones de fragmentos génicos biodiversos
ES2265663T3 (es) Acido nucleico que codifica un factor de conservacion de celulas madre derivado de la lectina.
AU2002339423B2 (en) Organo-phosphorous compounds for activating gamma/delta T cells
Murgola et al. Codon context effects in missense suppression
HUE027064T2 (hu) Fokozott immunstimuláns aktivitású, hidrofób T-analógokat tartalmazó CPG oligonukleotid-analógok
ES2675104T3 (es) Moléculas de ácidos nucleicos que codifican una dextrano-sacarasa que cataliza la síntesis de dextrano que porta ramificaciones de tipo alfa-1,2 osídicas
CA2865248A1 (en) Synthetic lipid biology for combinatorial engineering of endotoxin
US20110129883A1 (en) Inactivation of genes of the mep pathway
ES2283399T3 (es) Peptidomimetico de gd3.
CN108300726A (zh) α-红没药醇合成质粒及其构建方法与大肠杆菌工程菌株
ES2553763T3 (es) Mutantes de Francisella tularensis y usos de los mismos
ES2321602T3 (es) Composicion para fomentar la proliferacion de lactobacillus casei subsp.casei.
ES2215100T3 (es) Toxina selenocosmia huwena y utilizaciones terapeuticas de la misma.
BRPI0511793B1 (pt) proteínas quiméricas isoladas de lumazina sintase modificada
ES2280098T3 (es) Oligonucleotidos antisentido contra timidilato sintasa.
ES2250965T3 (es) Agente que contiene una cinasa de serina - treonina, para la terapia de tumores y el diagnostico de tumores.
US20050203037A1 (en) Complex immuno-gene medical composition for inhibiting tumor cells
ES2327389T3 (es) Operon de caucho aislado de xylella fastidiosa, moleculas de acido nucleico aisladas del mismo, y usos del mismo.
WO2000012120A1 (en) A pharmaceutical composition containing calcineurin b subunit